Clinical Trials Directory

Trials / Completed

CompletedNCT06224790

Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy

Effectiveness & Safety of Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy: A Randomized Controlled Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Sidrah Lodhi · Academic / Other
Sex
All
Age
30 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy

Conditions

Interventions

TypeNameDescription
DRUGPirfenidoneCapsule Pirfenidone 1200mg/ day in divided doses for 3 months
OTHERPlacebo2 Capsules 3 times a day for 3 months

Timeline

Start date
2024-03-10
Primary completion
2025-03-07
Completion
2025-03-07
First posted
2024-01-25
Last updated
2025-03-11

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT06224790. Inclusion in this directory is not an endorsement.